Journal Mobile Options
Table of Contents
Vol. 54, No. 3, 2008
Issue release date: July 2008
Section title: Experimental Chemotherapy
Chemotherapy 2008;54:176–180
(DOI:10.1159/000140361)

Potent in vitro Activity of the Albumin Fusion Type 1 Interferons (Albumin-Interferon-Alpha and Albumin-Interferon-Beta) against RNA Viral Agents of Bioterrorism and the Severe Acute Respiratory Syndrome (SARS) Virus

Subramanian G.M. · Moore P.A. · Gowen B.B. · Olsen A.L. · Barnard D.L. · Paragas J. · Hogan R.J. · Sidwell R.W.
aHuman Genome Sciences, Inc., Rockville, Md., bInstitute of Antiviral Research, Utah State University, Logan, Utah, cUS Army Medical Research Institute of Infectious Diseases, Fort Detrick, Md., and dUniversity of Georgia, Athens, Ga., USA

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Experimental Chemotherapy

Received: 4/30/2007
Accepted: 3/3/2008
Published online: 6/18/2008

Number of Print Pages: 5
Number of Figures: 2
Number of Tables: 1

ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)

For additional information: http://www.karger.com/CHE

Abstract

Background: The type 1 interferons (INF-α and INF-β) are potent antiviral agents. Albumin-INF-α and albumin-INF-β are novel recombinant proteins consisting of IFN-α or IFN-β genetically fused to human albumin. Methods: The in vitro antiviral activity of albumin-IFN-α was evaluated against representative bioterrorism viral agents and the severe acute respiratory syndrome virus. Antiviral activity was assessed using inhibition of cytopathic effect and neutral red staining. Results: EC50 values for albumin-IFN-α ranged from <0.1 ng/ml for Punta Toro virus to 65 ng/ml for Venezuelan equine encephalitis virus in the neutral red assay. Albumin-IFN-β showed 75- and 360-fold greater in vitro activity than albumin-IFN-α against Ebola virus and severe acute respiratory syndrome, respectively. Conclusion: Further evaluation of these long-acting albumin-IFN fusion proteins as prophylactic or therapeutic agents against these viral agents of bioterrorism in relevant primate models is warranted.


  

Author Contacts

G. Mani Subramanian, MD, PhD
Human Genome Sciences, Inc., 14200 Shady Grove Road
Rockville, MD 20850 (USA)
Tel. +1 301 315 2771, Fax +1 301 279 8799, E-Mail Mani_Subramanian@hgsi.com

  

Article Information

G.M.S. and P.A.M. were employed full time by Human Genome Sciences, Inc., at the time of conduct of the project.

Received: April 30, 2007
Accepted after revision: March 3, 2008
Published online: Juni 18, 2008
Number of Print Pages : 5
Number of Figures : 2, Number of Tables : 1, Number of References : 22

  

Publication Details

Chemotherapy (International Journal of Experimental and Clinical Chemotherapy)

Vol. 54, No. 3, Year 2008 (Cover Date: July 2008)

Journal Editor: Sörgel F. (Nürnberg-Heroldsberg)
ISSN: 0009–3157 (Print), eISSN: 1421–9794 (Online)

For additional information: http://www.karger.com/CHE


Article / Publication Details

First-Page Preview
Abstract of Experimental Chemotherapy

Received: 4/30/2007
Accepted: 3/3/2008
Published online: 6/18/2008

Number of Print Pages: 5
Number of Figures: 2
Number of Tables: 1

ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)

For additional information: http://www.karger.com/CHE


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.